Hutchison China Meditech Limited Grant of share options under share option scheme (4824P)

TIDMHCM

RNS Number : 4824P

Hutchison China Meditech Limited

10 October 2019

Grant of Share Options under Share Option Scheme

London: Thursday, October 10, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on October 9, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme").

Chi-Med granted 1,735,000 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:

 
 Date of grant                      :   October 9, 2019 
 Exercise price of share options    :   GBP2.978 per Ordinary Share 
  granted 
 Number of share options granted    :   1,735,000 (each share option shall 
                                         entitle the holder thereof to subscribe 
                                         for one Ordinary Share) 
 Closing market price of Ordinary   :   GBP2.8775 per Ordinary Share 
  Shares on the date of grant 
 Validity period of the share       :   From October 9, 2019 to October 
  options                                8, 2029 
 

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 470 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                             [phone] 
  Annie Cheng, Vice President                                 [phone] 
  David Dible, Citigate Dewe Rogerson                         [phone] (Mobile) 
                                                               [e-mail] 
  Xuan Yang, Solebury Trout                                   [phone] (Mobile) 
                                                               [e-mail] 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson      [phone] (Mobile) 
                                                               [e-mail] 
  Americas - Brad Miles, Solebury Trout                       [phone] (Mobile) 
                                                               [e-mail] 
  Hong Kong & Asia ex-China     - Joseph Chi Lo, Brunswick    [phone] (Mobile) 
                                                               [e-mail] 
                                - Zhou Yi, Brunswick          [phone] (Mobile) 
                                                               [e-mail] 
  Mainland China - Sam Shen, Edelman                          [phone] (Mobile) 
                                                               [e-mail] 
 
Nominated Advisor 
  Atholl Tweedie, Panmure Gordon (UK) Limited                 [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEANEEFFNNFEF

(END) Dow Jones Newswires

October 10, 2019 05:22 ET (09:22 GMT)